Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles

Zika virus (ZIKV) infections are typically asymptomatic but cause severe neurological complications (e.g. Guillain–Barré syndrome in adults, and microcephaly in newborns). There are currently no specific therapy or vaccine options available to prevent ZIKV infections. Temporal gene expression profil...

Full description

Saved in:
Bibliographic Details
Main Authors: Nailou Zhang, Zhongyuan Tan, Jinbo Wei, Sai Zhang, Yan Liu, Yuanjiu Miao, Qingwen Ding, Wenfu Yi, Min Gan, Chunjie Li, Bin Liu, Hanzhong Wang, Zhenhua Zheng
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Emerging Microbes and Infections
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2023.2174777
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850278934472556544
author Nailou Zhang
Zhongyuan Tan
Jinbo Wei
Sai Zhang
Yan Liu
Yuanjiu Miao
Qingwen Ding
Wenfu Yi
Min Gan
Chunjie Li
Bin Liu
Hanzhong Wang
Zhenhua Zheng
author_facet Nailou Zhang
Zhongyuan Tan
Jinbo Wei
Sai Zhang
Yan Liu
Yuanjiu Miao
Qingwen Ding
Wenfu Yi
Min Gan
Chunjie Li
Bin Liu
Hanzhong Wang
Zhenhua Zheng
author_sort Nailou Zhang
collection DOAJ
description Zika virus (ZIKV) infections are typically asymptomatic but cause severe neurological complications (e.g. Guillain–Barré syndrome in adults, and microcephaly in newborns). There are currently no specific therapy or vaccine options available to prevent ZIKV infections. Temporal gene expression profiles of ZIKV-infected human brain microvascular endothelial cells (HBMECs) were used in this study to identify genes essential for viral replication. These genes were then used to identify novel anti-ZIKV agents and validated in publicly available data and functional wet-lab experiments. Here, we found that ZIKV effectively evaded activation of immune response-related genes and completely reprogrammed cellular transcriptional architectures. Knockdown of genes, which gradually upregulated during viral infection but showed distinct expression patterns between ZIKV- and mock infection, discovered novel proviral and antiviral factors. One-third of the 74 drugs found through signature-based drug repositioning and cross-reference with the Drug Gene Interaction Database (DGIdb) were known anti-ZIKV agents. In cellular assays, two promising antiviral candidates (Luminespib/NVP-AUY922, L-161982) were found to reduce viral replication without causing cell toxicity. Overall, our time-series transcriptome-based methods offer a novel and feasible strategy for antiviral drug discovery. Our strategies, which combine conventional and data-driven analysis, can be extended for other pathogens causing pandemics in the future.
format Article
id doaj-art-9efaac8c64e940cdb97d2d5431ae857c
institution OA Journals
issn 2222-1751
language English
publishDate 2023-12-01
publisher Taylor & Francis Group
record_format Article
series Emerging Microbes and Infections
spelling doaj-art-9efaac8c64e940cdb97d2d5431ae857c2025-08-20T01:49:16ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512023-12-0112110.1080/22221751.2023.2174777Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profilesNailou Zhang0Zhongyuan Tan1Jinbo Wei2Sai Zhang3Yan Liu4Yuanjiu Miao5Qingwen Ding6Wenfu Yi7Min Gan8Chunjie Li9Bin Liu10Hanzhong Wang11Zhenhua Zheng12CAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaThe Joint Laboratory for Translational Precision Medicine, a. Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, People's Republic of China and b. Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, People's Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCharacteristic Medical Center of Chinese People’s Armed Police Forces, Tianjin, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCAS Key Laboratory of Special Pathogens and Biosafety, Center for Emerging Infectious Diseases, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaZika virus (ZIKV) infections are typically asymptomatic but cause severe neurological complications (e.g. Guillain–Barré syndrome in adults, and microcephaly in newborns). There are currently no specific therapy or vaccine options available to prevent ZIKV infections. Temporal gene expression profiles of ZIKV-infected human brain microvascular endothelial cells (HBMECs) were used in this study to identify genes essential for viral replication. These genes were then used to identify novel anti-ZIKV agents and validated in publicly available data and functional wet-lab experiments. Here, we found that ZIKV effectively evaded activation of immune response-related genes and completely reprogrammed cellular transcriptional architectures. Knockdown of genes, which gradually upregulated during viral infection but showed distinct expression patterns between ZIKV- and mock infection, discovered novel proviral and antiviral factors. One-third of the 74 drugs found through signature-based drug repositioning and cross-reference with the Drug Gene Interaction Database (DGIdb) were known anti-ZIKV agents. In cellular assays, two promising antiviral candidates (Luminespib/NVP-AUY922, L-161982) were found to reduce viral replication without causing cell toxicity. Overall, our time-series transcriptome-based methods offer a novel and feasible strategy for antiviral drug discovery. Our strategies, which combine conventional and data-driven analysis, can be extended for other pathogens causing pandemics in the future.https://www.tandfonline.com/doi/10.1080/22221751.2023.2174777ZIKVtemporal transcriptomedrug repurposingantiviralsviral infection mechanisms
spellingShingle Nailou Zhang
Zhongyuan Tan
Jinbo Wei
Sai Zhang
Yan Liu
Yuanjiu Miao
Qingwen Ding
Wenfu Yi
Min Gan
Chunjie Li
Bin Liu
Hanzhong Wang
Zhenhua Zheng
Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
Emerging Microbes and Infections
ZIKV
temporal transcriptome
drug repurposing
antivirals
viral infection mechanisms
title Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
title_full Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
title_fullStr Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
title_full_unstemmed Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
title_short Identification of novel anti-ZIKV drugs from viral-infection temporal gene expression profiles
title_sort identification of novel anti zikv drugs from viral infection temporal gene expression profiles
topic ZIKV
temporal transcriptome
drug repurposing
antivirals
viral infection mechanisms
url https://www.tandfonline.com/doi/10.1080/22221751.2023.2174777
work_keys_str_mv AT nailouzhang identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT zhongyuantan identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT jinbowei identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT saizhang identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT yanliu identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT yuanjiumiao identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT qingwending identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT wenfuyi identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT mingan identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT chunjieli identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT binliu identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT hanzhongwang identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles
AT zhenhuazheng identificationofnovelantizikvdrugsfromviralinfectiontemporalgeneexpressionprofiles